ifosfamide and Cancer of Lung studies

Research Excerpts

Excerpt	Relevance	Reference
"This Phase II trial of paclitaxel/ifosfamide included patients with bi-dimensionally measurable metastatic breast cancer in second or third relapse, following anthracycline-containing regimens; ECOG PS < 2, and adequate hepatic, cardiac, renal, and hematological functions."	9.08	Phase II trial of paclitaxel and ifosfamide as a salvage treatment in metastatic breast cancer. ( Amorim, WC; Ferreira-Filho, AF; Guimaraes, RC; Morici, AC; Murad, AM; Schwartsmann, G, 1997)
"This Phase I/II study investigates increasingly high doses of ifosfamide combined with full dose doxorubicin chemotherapy supported with peripheral blood stem cells (PBSC) and granulocyte-colony stimulating factor (G-CSF) in patients with metastatic soft tissue sarcoma (STS)."	9.08	A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. ( Arseniev, L; Bokemeyer, C; Franzke, A; Hartmann, JT; Kanz, L; Link, H; Metzner, B; Schmoll, HJ; Schöber, C, 1997)
"To investigate the value of contrast-enhanced computed tomography (CECT) radiomics features in predicting the efficacy of epirubicin combined with ifosfamide in patients with pulmonary metastases from soft tissue sarcoma."	8.12	Prediction of the therapeutic efficacy of epirubicin combined with ifosfamide in patients with lung metastases from soft tissue sarcoma based on contrast-enhanced CT radiomics features. ( Jiang, X; Li, M; Ma, ST; Miao, L; Wang, YM; Zhang, HH, 2022)
"This case shows us that operation on late stage cardiac angiosarcomas can alleviate a patient's symptoms; postoperative paclitaxel monotherapy was insufficient and ifosfamide and epirubicin plus recombinant human endostatin has a limited effect on late stage cardiac angiosarcoma."	7.91	The effect of ifosfamide, epirubicin, and recombinant human endostatin therapy on a cardiac angiosarcoma: A case report. ( Davies, H; Jiang, L; Shi, K; Xu, X, 2019)
"The aim of this retrospective study was to evaluate the feasibility and efficacy of response to continuous-infusion ifosfamide and doxorubicin combination as second-line chemotherapy for patients with recurrent or refractory osteosarcoma."	7.81	Continuous-infusion ifosfamide and doxorubicin combination as second-line chemotherapy for recurrent or refractory osteosarcoma patients in China: a retrospective study. ( He, AN; Huang, YJ; Min, DL; Shen, Z; Sun, YJ; Yao, Y, 2015)
"To determine demographic data, prognostic factors and outcome of childhood osteosarcoma treated with a carboplatin-based chemotherapeutic protocol at Chiang Mai University."	7.79	Carboplatin and doxorubicin in treatment of pediatric osteosarcoma: a 9-year single institute experience in the Northern Region of Thailand. ( Charoenkwan, P; Choeyprasert, W; Natesirinilkul, R; Sittipreechacharn, S, 2013)
"This study assessed the therapeutic effect of and adverse reactions to pirarubicin (THP) chemotherapy in osteosarcoma patients with lung metastasis, and analyzed the relationship between THP therapeutic effect and expression of p-glycoprotein and topoisomerase-II."	7.76	Therapeutic effect of pirarubicin-based chemotherapy for osteosarcoma patients with lung metastasis. ( Chen, P; Lin, F; Sun, Y; Wang, Z; Yao, Y; Zhao, H, 2010)
"We report a patient with primary lung adenocarcinoma who had Ewing's sarcoma and was successfully treated with ifosfamide."	7.74	[A case of primary lung adenocarcinoma accompanied by Ewing's sarcoma successfully treated with ifosfamide]. ( Arai, H; Fukumura, H; Kudo, M; Masuda, M; Nakajima, K; Oshiro, H; Rino, Y; Wada, N; Watanuki, Y; Yamanaka, S; Yukawa, N, 2008)
"Cyclophosphamide (CTX) and ifosfamide (IFX) are alkylating agents used to treat osteosarcoma (OS)."	7.73	Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases. ( Duan, X; Jia, SF; Kleinerman, ES; Koshkina, N, 2006)
"Ifosfamide, Carboplatin and Etoposide (ICE) therapy was used to treat 4 patients, 2 with refractory osteosarcoma, and one each with relapsed brain tumor and newly diagnosed brain tumor."	7.70	[Pilot study of relapsed osteosarcoma and brain tumor with ifosfamide, carboplatin and etoposide (ICE therapy)]. ( Agata, H; Fujimoto, T; Hamaguchi, N; Hirota, T; Iwata, A; Katano, N; Kitagawa, S; Kobayashi, S; Konno, K; Sato, T; Sawada, K; Takeuchi, M, 1998)
"Generalized and partial seizures with secondary generalization were observed during ifosfamide-mesna (IFO) treatment in a patient with lung epidermoid carcinoma."	7.69	[Epileptic seizures and treatment with ifosfamide-mesna]. ( Farisse, P; Somma-Mauvais, H; Viallat, JR, 1994)
" A 16-year-old girl with metastatic osteosarcoma experienced recurrent bouts of symptomatic pancreatitis 24 hours after treatment with ifosfamide administered as a single agent."	7.69	Acute pancreatitis after ifosfamide therapy. ( Adamson, PC; Balis, FM; Blaney, SM; Izraeli, S, 1994)
"From January 1990 to December 1995 we treated 35 patients (pts) with bone and soft tissue sarcoma with ifosfamide (IFM)."	7.69	[The effects of high-dose ifosfamide in the treatment of bone and soft tissue sarcomas]. ( Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T; Yonemoto, T, 1997)
"Forty seven patients with inoperable adenocarcinoma and large cell carcinoma of the lung were treated with a combination of cisplatin (25 mg/m2), ifosfamide (1."	7.68	[Clinical study of combination chemotherapy with cisplatin, ifosfamide, 5-FU (CIF therapy) of inoperable adenocarcinoma and large cell carcinoma of the lung]. ( Asakawa, M; Fujita, A; Honda, R; Inoue, Y; Mori, T; Nakajima, S; Sasaki, H; Sekine, K; Suzuki, A, 1991)
"A 13-year-old boy with unresectable pulmonary metastatic osteosarcoma, which was refractory to high dose methotrexate, adriamycin, cisplatin and combination of bleomycin, cyclophosphamide and actinomycin D, was treated by aggressive chemotherapy including the combination of ifosfamide (1 g/m2 x day 1-4), Carboplatin (100 mg/m2 x day 1-4) and Vindesine (4 mg/m2 x day 1)."	7.68	[Successful treatment of metastatic and refractory osteosarcoma by ifosfamide, carboplatin and vindesine: case report]. ( Fujita, H; Ishimoto, K; Kiyokawa, N; Kyo, K; Mizuno, T; Takada, K; Yabuta, K, 1991)
"The mesna, doxorubicin, ifosfamide, dacarbazine regimen produced a 47% response rate (including 10% complete responses) in 105 eligible adults with advanced sarcoma."	7.68	Mesna, doxorubicin, ifosfamide, dacarbazine (MAID) regimen for adults with advanced sarcoma. ( Aisner, J; Antman, KH; Elias, A; Ryan, L, 1990)
"Thirty-seven patients with widely metastatic malignant melanoma were treated with one of three chemotherapy regimens, incorporating high-dose dacarbazine (DTIC)."	7.67	High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma. ( Carr, T; Chadwick, G; Craig, P; Jones, R; Lind, M; Morgenstern, G; Thatcher, D, 1989)
"Fifty-three patients with inoperable non-small cell bronchial carcinoma were treated at four-weekly intervals with two cytostatic drugs, doxorubicin (50 mg/m2 on day 1) and ifosfamide (2000 mg/m2 on days 1-3)."	7.66	[Combined cytostatic chemotherapy of advanced non-small-cell bronchial carcinoma with doxorubicin and ifosfamide]. ( Göbel, D; Matthiessen, W; Stempinski, E; Thalmann, U, 1983)
" Both have a dose-response relationship."	6.68	Phase II study of a closely spaced ifosfamide--cisplatin schedule with the addition of G-CSF in advanced non-small-cell lung cancer and malignant melanoma. ( de Wit, R; Planting, AS; Stoter, G; van der Burg, ME; Verweij, J, 1996)
"Breast stromal sarcoma is very rare, accounting for less than 1% of mammary neoplasms, and the treatment strategy is not well established, especially regarding chemotherapy."	5.37	Stromal sarcoma of the breast with lung metastases showing a clinical complete response to doxorubicin plus ifosfamide treatment: report of a case. ( Inoue, K; Iwase, H; Kuriwaki, K; Sueta, A; Yamamoto, Y, 2011)
"The European Organization for Research and Treatment of Cancer (EORTC) 62012 study was a Phase III trial of doxorubicin versus doxorubicin-ifosfamide chemotherapy in 455 patients with advanced soft tissue sarcoma (STS)."	5.24	Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study. ( Collin, F; Daugaard, S; Fisher, C; Gronchi, A; Grünwald, V; Hogendoorn, PCW; Judson, I; Lia, M; Litière, S; Mechtersheimer, G; Messiou, C; Sciot, R; van der Graaf, W; Wardelmann, E; Young, RJ, 2017)
"Patients with high-grade soft tissue sarcomas were treated with 2 cycles of ifosfamide, mitomycin, doxorubicin, and cisplatin plus GM-CSF subcutaneous followed by 45 Gy irradiation with concurrent 2 cycles of mitomycin, doxorubicin, and cisplatin followed by surgery +/- intraoperative radiation or brachytherapy."	5.22	Chemotherapy, Irradiation, and Surgery for Function-preserving Curative Therapy of Primary Extremity Soft Tissue Sarcomas: Initial Treatment With I-MAP and Inhalation GM-CSF During Preoperative Irradiation and Postoperatively. ( Haddock, M; Mahoney, M; Maples, W; Markovic, SN; O'Connor, MI; Okuno, S; Petersen, I; Shives, T; Sim, F, 2016)
"To compare three-drug chemotherapy with cisplatin, doxorubicin, and methotrexate with four-drug chemotherapy with cisplatin, doxorubicin, methotrexate, and ifosfamide for the treatment of osteosarcoma."	5.13	Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. ( Bernstein, ML; Betcher, D; Ferguson, WS; Gebhardt, MC; Goorin, AM; Grier, HE; Harris, M; Healey, JH; Kleinerman, E; Krailo, MD; Link, MP; Meyers, PA; Nadel, H; Nieder, M; Schwartz, CL; Siegal, GP; Weiner, MA; Wells, RJ; Womer, RB, 2008)
"The outcome of patients with metastatic osteosarcoma treated in two consecutive trials from 1986 to 1997 was analyzed to evaluate the efficacy of carboplatin-based multiagent chemotherapy and to identify prognostic factors."	5.12	Metastatic osteosarcoma. ( Billups, CA; Cain, AM; Daw, NC; Jenkins, JJ; McCarville, MB; Meyer, WH; Neel, MD; Rao, BN; Rodriguez-Galindo, C, 2006)
"A phase IIb trial using liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE) in combination with ifosfamide (IFX) for patients with relapsed osteosarcoma was undertaken to determine (a) the tolerability of the combination therapy, (b) if L-MTP-PE increased the toxicity of IFX, and (c) whether IFX altered or suppressed the in vivo immune response to L-MTP-PE."	5.08	Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation. ( Gano, JB; Jaffe, N; Jia, SF; Kleinerman, ES; Meyers, PA; Raymond, AK, 1995)
"This Phase II trial of paclitaxel/ifosfamide included patients with bi-dimensionally measurable metastatic breast cancer in second or third relapse, following anthracycline-containing regimens; ECOG PS < 2, and adequate hepatic, cardiac, renal, and hematological functions."	5.08	Phase II trial of paclitaxel and ifosfamide as a salvage treatment in metastatic breast cancer. ( Amorim, WC; Ferreira-Filho, AF; Guimaraes, RC; Morici, AC; Murad, AM; Schwartsmann, G, 1997)
"This Phase I/II study investigates increasingly high doses of ifosfamide combined with full dose doxorubicin chemotherapy supported with peripheral blood stem cells (PBSC) and granulocyte-colony stimulating factor (G-CSF) in patients with metastatic soft tissue sarcoma (STS)."	5.08	A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. ( Arseniev, L; Bokemeyer, C; Franzke, A; Hartmann, JT; Kanz, L; Link, H; Metzner, B; Schmoll, HJ; Schöber, C, 1997)
"To estimate the duration of survival (S) of patients with metastatic osteosarcoma (MOS) at diagnosis treated with a multiagent, ifosfamide-containing chemotherapeutic and surgical regimen and to evaluate the toxicity of this regimen."	5.08	Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study. ( Ayala, A; Ferguson, WS; Gieser, P; Goorin, AM; Harris, MB; Holbrook, T; Link, MP; Shochat, SJ, 1998)
"43 patients with metastasizing sarcomas were treated with a combination of either vincristin, adriamycin and cis-platinum (n = 21) or ifosfamide and cis-platinum at three weeks' intervals in each case."	5.05	[Chemotherapy in advanced sarcomas (author's transl)]. ( Bierbaum, W; Bremer, K; Firusian, N; Higi, M; Niederle, N; Scheulen, ME; Schmidt, CG; Seeber, S, 1981)
"A patient with a small-cell lung cancer (SCLC) developed an asymptomatic hyponatremia, with all features of the syndrome of inappropriate antidiuretic hormone secretion (SIADH), two days after the start of his first cycle of chemotherapy with vindesine, ifosfamide and cisplatin."	4.80	Syndrome of inappropriate antidiuretic hormone associated with chemotherapy-induced tumour lysis in small-cell lung cancer: case report and literature review. ( Paridaens, R; Vanhees, SL; Vansteenkiste, JF, 2000)
"The authors describe skin pigment changes in a 5-year-old patient receiving ifosfamide, MESNA, and etoposide for the treatment of relapsed Wilms tumor."	4.78	Ifosfamide-induced hyperpigmentation. ( Cornelius, AS; Murry, DJ; Teresi, ME, 1993)
"The alkylating agent ifosfamide, an analog of cyclophosphamide, has demonstrated significant activity in soft tissue sarcoma and testicular carcinoma."	4.77	Ifosfamide. ( Baker, LH; Zalupski, M, 1988)
"To investigate the value of contrast-enhanced computed tomography (CECT) radiomics features in predicting the efficacy of epirubicin combined with ifosfamide in patients with pulmonary metastases from soft tissue sarcoma."	4.12	Prediction of the therapeutic efficacy of epirubicin combined with ifosfamide in patients with lung metastases from soft tissue sarcoma based on contrast-enhanced CT radiomics features. ( Jiang, X; Li, M; Ma, ST; Miao, L; Wang, YM; Zhang, HH, 2022)
"This case shows us that operation on late stage cardiac angiosarcomas can alleviate a patient's symptoms; postoperative paclitaxel monotherapy was insufficient and ifosfamide and epirubicin plus recombinant human endostatin has a limited effect on late stage cardiac angiosarcoma."	3.91	The effect of ifosfamide, epirubicin, and recombinant human endostatin therapy on a cardiac angiosarcoma: A case report. ( Davies, H; Jiang, L; Shi, K; Xu, X, 2019)
"The aim of this retrospective study was to evaluate the feasibility and efficacy of response to continuous-infusion ifosfamide and doxorubicin combination as second-line chemotherapy for patients with recurrent or refractory osteosarcoma."	3.81	Continuous-infusion ifosfamide and doxorubicin combination as second-line chemotherapy for recurrent or refractory osteosarcoma patients in China: a retrospective study. ( He, AN; Huang, YJ; Min, DL; Shen, Z; Sun, YJ; Yao, Y, 2015)
"We reviewed the records of 50 patients with osteosarcoma who underwent marginal resection following effective preoperative chemotherapy; 18 were treated with the MMIA (high-dose methotrexate (HD-MTX), adriamycin (ADR), ifosfamide (IFO)) and cisplatin (DDP), and 32 patients were treated with the DIA (DDP, ADR and IFO)."	3.80	Marginal resection for osteosarcoma with effective neoadjuvant chemotherapy: long-term outcomes. ( Xu, M; Xu, S; Yu, X, 2014)
"To determine demographic data, prognostic factors and outcome of childhood osteosarcoma treated with a carboplatin-based chemotherapeutic protocol at Chiang Mai University."	3.79	Carboplatin and doxorubicin in treatment of pediatric osteosarcoma: a 9-year single institute experience in the Northern Region of Thailand. ( Charoenkwan, P; Choeyprasert, W; Natesirinilkul, R; Sittipreechacharn, S, 2013)
"This study assessed the therapeutic effect of and adverse reactions to pirarubicin (THP) chemotherapy in osteosarcoma patients with lung metastasis, and analyzed the relationship between THP therapeutic effect and expression of p-glycoprotein and topoisomerase-II."	3.76	Therapeutic effect of pirarubicin-based chemotherapy for osteosarcoma patients with lung metastasis. ( Chen, P; Lin, F; Sun, Y; Wang, Z; Yao, Y; Zhao, H, 2010)
"We report a patient with primary lung adenocarcinoma who had Ewing's sarcoma and was successfully treated with ifosfamide."	3.74	[A case of primary lung adenocarcinoma accompanied by Ewing's sarcoma successfully treated with ifosfamide]. ( Arai, H; Fukumura, H; Kudo, M; Masuda, M; Nakajima, K; Oshiro, H; Rino, Y; Wada, N; Watanuki, Y; Yamanaka, S; Yukawa, N, 2008)
"Cyclophosphamide (CTX) and ifosfamide (IFX) are alkylating agents used to treat osteosarcoma (OS)."	3.73	Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases. ( Duan, X; Jia, SF; Kleinerman, ES; Koshkina, N, 2006)
"Ifosfamide, Carboplatin and Etoposide (ICE) therapy was used to treat 4 patients, 2 with refractory osteosarcoma, and one each with relapsed brain tumor and newly diagnosed brain tumor."	3.70	[Pilot study of relapsed osteosarcoma and brain tumor with ifosfamide, carboplatin and etoposide (ICE therapy)]. ( Agata, H; Fujimoto, T; Hamaguchi, N; Hirota, T; Iwata, A; Katano, N; Kitagawa, S; Kobayashi, S; Konno, K; Sato, T; Sawada, K; Takeuchi, M, 1998)
"In three new approved indications (non Hodgkin's lymphoma, Hodgkin's lymphoma and acute lymphoblastic leukaemia) and in three previously existing indications (ovarian cancer, soft tissue sarcomas and osteogenic sarcomas), non comparative trials show that ifosfamide can induce tumour regression in patients who relapse after a first course of chemotherapy (sometimes containing cyclophosphamide)."	3.70	Ifosfamide: new idications-new dose strength. Limited evidence of effectiveness. ( , 1998)
"Generalized and partial seizures with secondary generalization were observed during ifosfamide-mesna (IFO) treatment in a patient with lung epidermoid carcinoma."	3.69	[Epileptic seizures and treatment with ifosfamide-mesna]. ( Farisse, P; Somma-Mauvais, H; Viallat, JR, 1994)
" A 16-year-old girl with metastatic osteosarcoma experienced recurrent bouts of symptomatic pancreatitis 24 hours after treatment with ifosfamide administered as a single agent."	3.69	Acute pancreatitis after ifosfamide therapy. ( Adamson, PC; Balis, FM; Blaney, SM; Izraeli, S, 1994)
"Patients with advanced adenocarcinoma of the lung with measurable or assessable disease received chemotherapy with mesna, ifosfamide, carboplatin, and etoposide (MICE)."	3.69	Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study. ( Boerrigter, L; Mooi, WJ; Rodenhuis, S; Slebos, RJ; Top, B; van Zandwijk, N; van't Veer, L, 1997)
"Patients with lung metastases originating from an osteosarcoma of the extremity received chemotherapy (high dose methotrexate, cisplatin, doxorubicin, and ifosfamide) followed by simultaneous resection of primary and metastatic lesions and additional chemotherapy."	3.69	Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions. ( Bacci, G; Bertoni, F; Briccoli, A; Donati, D; Ferrari, S; Forni, C; Manfrini, M; Mercuri, M; Monti, C; Zanoni, A, 1997)
"From January 1990 to December 1995 we treated 35 patients (pts) with bone and soft tissue sarcoma with ifosfamide (IFM)."	3.69	[The effects of high-dose ifosfamide in the treatment of bone and soft tissue sarcomas]. ( Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T; Yonemoto, T, 1997)
"The series of 9 compounds, including 3 racemates and 6 enantiomers of bromine-substituted analogues of ifosfamide (bromo-, chlorobromo- and dibromofosfamides) have been evaluated for antitumor activity against L1210 leukemia, Lewis lung carcinoma and B16 melanoma in mice."	3.68	Antitumor activity evaluation of bromine-substituted analogues of ifosfamide. I. Stereodifferentiation of biological effects and selection of the most potent compounds. ( Glazman-Kuśnierczyk, H; Matuszyk, J; Radzikowski, C, 1992)
"Forty seven patients with inoperable adenocarcinoma and large cell carcinoma of the lung were treated with a combination of cisplatin (25 mg/m2), ifosfamide (1."	3.68	[Clinical study of combination chemotherapy with cisplatin, ifosfamide, 5-FU (CIF therapy) of inoperable adenocarcinoma and large cell carcinoma of the lung]. ( Asakawa, M; Fujita, A; Honda, R; Inoue, Y; Mori, T; Nakajima, S; Sasaki, H; Sekine, K; Suzuki, A, 1991)
"A 13-year-old boy with unresectable pulmonary metastatic osteosarcoma, which was refractory to high dose methotrexate, adriamycin, cisplatin and combination of bleomycin, cyclophosphamide and actinomycin D, was treated by aggressive chemotherapy including the combination of ifosfamide (1 g/m2 x day 1-4), Carboplatin (100 mg/m2 x day 1-4) and Vindesine (4 mg/m2 x day 1)."	3.68	[Successful treatment of metastatic and refractory osteosarcoma by ifosfamide, carboplatin and vindesine: case report]. ( Fujita, H; Ishimoto, K; Kiyokawa, N; Kyo, K; Mizuno, T; Takada, K; Yabuta, K, 1991)
"The mesna, doxorubicin, ifosfamide, dacarbazine regimen produced a 47% response rate (including 10% complete responses) in 105 eligible adults with advanced sarcoma."	3.68	Mesna, doxorubicin, ifosfamide, dacarbazine (MAID) regimen for adults with advanced sarcoma. ( Aisner, J; Antman, KH; Elias, A; Ryan, L, 1990)
"Thirty-seven patients with widely metastatic malignant melanoma were treated with one of three chemotherapy regimens, incorporating high-dose dacarbazine (DTIC)."	3.67	High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma. ( Carr, T; Chadwick, G; Craig, P; Jones, R; Lind, M; Morgenstern, G; Thatcher, D, 1989)
"Fifty-three patients with inoperable non-small cell bronchial carcinoma were treated at four-weekly intervals with two cytostatic drugs, doxorubicin (50 mg/m2 on day 1) and ifosfamide (2000 mg/m2 on days 1-3)."	3.66	[Combined cytostatic chemotherapy of advanced non-small-cell bronchial carcinoma with doxorubicin and ifosfamide]. ( Göbel, D; Matthiessen, W; Stempinski, E; Thalmann, U, 1983)
" This phase II study evaluated the efficacy and safety of IFM combination with recommended current supportive therapy for recurrent SCLC in second-line and heavily treated setting."	2.87	A phase II trial of Ifosfamide combination with recommended supportive therapy for recurrent SCLC in second-line and heavily treated setting. ( Fukatsu, A; Hase, T; Hasegawa, Y; Hayashi, H; Kawada, K; Kondo, M; Morise, M; Nomura, F; Sokai, A; Tanaka, I, 2018)
"Ifosfamide is a chloro-isophosphoramide prodrug activated by hepatic Cytochrome P450 enzymes."	2.82	Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models. ( Ahluwalia, D; Ferraro, DJ; Hart, CP; Jung, D; Liu, Q; Matteucci, MD; Sun, JD; Wang, Y, 2016)
"The European Intergroup Cooperative Ewing's Sarcoma Study investigated whether cyclophosphamide has a similar efficacy as ifosfamide in standard-risk (SR) patients and whether the addition of etoposide improves survival in high-risk (HR) patients."	2.73	Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. ( Cassoni, A; Craft, AW; Douglas, C; Dunst, J; Grimer, R; Hackshaw, A; Hunold, A; Jürgens, H; Köhler, G; Ladenstein, R; Lewis, I; McTiernan, A; Paulussen, M; Poremba, C; Schuck, A; Spooner, D; van den Berg, H; Whelan, J; Winkelmann, W; Zoubek, A, 2008)
"To investigate the prognostic value of systemic exposure to etoposide (Area Under the concentration Curve (AUC(VP16))) on overall survival (OS) in patients with small cell lung cancer (SCLC)."	2.73	Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study. ( Chabaud, S; Court-Fortune, I; Falandry, C; Fournel, C; Freyer, G; Girard, P; Ribba, B; Souquet, PJ; Tod, M; Tranchand, B; Trillet-Lenoir, V; You, B, 2008)
"Paclitaxel was given at the dose of 200 mg/m iv in 3 hours, ifosfamide (with mesna) at the dose of 3 g/m and carboplatin at an area under the curve 5, on day 1, every 21 days for a total of six cycles in responding or stabilized patients."	2.71	Phase II study of Taxol combined With ifosfamide and carboplatin in the treatment of stage IIIb-IV non-small-cell lung cancer. ( Ardizzoni, A; Ariganello, O; Boni, C; Cafferata, MA; De Marinis, F; Meriggi, F; Neumaier, CE; Portalone, L; Rosso, R; Torri, V; Zaniboni, A, 2003)
"Ifosfamide is an active alkylating agent used in the first-line treatment of NSCLC."	2.71	Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel. ( Chen, MC; Chen, YM; Lee, CS; Lin, WC; Perng, RP; Shih, JF; Tsai, CM, 2003)
"Secondary objectives were time to disease progression, response rates, evaluation of toxicity, disease-related symptoms, World Health Organization performance status (PS), and quality of life (QoL)."	2.71	Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. ( Anderson, H; Ashcroft, L; Beresford, C; Burt, PA; Clemons, M; Danson, S; Dowd, I; Fairve-Finn, C; Hassan, J; Middleton, MR; O'Byrne, KJ; Ranson, M; Stout, R; Thatcher, N, 2003)
"Ifosfamide (I) has also been approved for NSCLC treatment."	2.71	Phase I study with dose escalation of gemcitabine and cisplatin in combination with ifosfamide (GIP) in patients with non-small-cell lung carcinoma. ( Billiart, I; Bourgeois, H; Chabrun, V; Chieze, S; Daban, A; Ferrand, V; Germain, T; Lemerre, D; Meurice, JC; Tourani, JM, 2004)
" Haematological toxicity and dosage reductions were higher with SuperMIP, which was nevertheless associated with a significantly increased absolute dose intensity."	2.71	A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer. ( Berghmans, T; Corhay, JL; Efremidis, A; Giner, V; Koumakis, G; Lafitte, JJ; Lecomte, J; Lothaire, P; Mommen, P; Ninane, V; Paesmans, M; Richez, M; Sculier, JP; Thiriaux, J; Van Houtte, P; Wackenier, P, 2004)
"Grade 3 thrombocytopenia was observed in five cases (36%)."	2.71	Combination chemotherapy of docetaxel, ifosfamide and cisplatin (DIP) in patients with metastatic urothelial cancer: a preliminary report. ( Kitamura, T; Kume, H; Matsumoto, S; Nishimatsu, H; Okamoto, N; Suzuki, M; Takahashi, S; Tomita, K, 2005)
"Grade 3-4 neutropenia was the dose limiting toxicity, observed in 36% of patients."	2.71	Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial. ( Brunetti, C; Cassano, G; Colucci, G; Galetta, D; Gebbia, V; Germano, D; Giampaglia, M; Guida, M; Izzi, G; Lorusso, V; Nettis, G; Silvestris, N; Spada, M, 2005)
"To find the maximum tolerated dose for ifosfamide in combination with paclitaxel and carboplatin in small-cell lung cancer patients (SCLC), who are resistant to cyclophosphamide, doxorubicin and etoposide (CDE)."	2.70	Dose-finding and pharmacological study of ifosfamide in combination with paclitaxel and carboplatin in resistant small-cell lung cancer. ( Beijnen, JH; Groen, HJ; Kerbush, T; Sleijfer, DT; Smit, EF; van Putten, JW; van Rijswijk, R, 2001)
" Peak concentration of 47 micrograms/ml was observed after 1 h."	2.70	Pharmacokinetics and toxicity of oral (-)-(S)-bromofosfamide in lung cancer patients. ( Gasiorek, M; Kobylińska, K; Kobylińska, M; Koralewski, P; Sobik, B, 2001)
"Neutropenia was the dose limiting toxicity (G1=6%, G2=11%, G3=10%, G4=7%)."	2.70	Vinorelbine, ifosfamide and cisplatin as first-line treatment in patients with inoperable non-small cell lung cancer. ( Camps, C; García, R; Maestu, I; Montalar, J; Morales, S; Segura, A; Torregrosa, D; Vadell, C; Yuste, AL, 2001)
" No toxic death was reported."	2.70	Gemcitabine, Ifosfamide and Navelbine (GIN): activity and safety of a non-platinum-based triplet in advanced non-small-cell lung cancer (NSCLC). ( Ardizzoni, A; Baldini, E; Boni, L; Cafferata, MA; Conte, PF; Neumaier, C; Prochilo, T; Rosso, R; Tibaldi, C, 2001)
"Paclitaxel was given after the first dose of ifosfamide on Day 1."	2.69	A Phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors. ( Berkowitz, R; Bunnell, CA; Buswell, L; Muto, M; Sheets, E; Shulman, LN; Thompson, L, 1998)
" The urinary profiles of mesna and dimesna excretion were determined on days 1, 2, and 5; pharmacokinetic parameters for blood samples were determined only on day 5."	2.69	Pharmacokinetics of an intravenous-oral versus intravenous-mesna regimen in lung cancer patients receiving ifosfamide. ( Anthony, LB; Brade, WP; Bush, DA; Frazier, MW; Goren, MP; Hande, KR; Johnson, DH; Li, JT, 1998)
"Gemcitabine was administered at a dose of 1,000 mg/m2 on days 1, 8, and 15, followed by a 1-week rest, while ifosfamide was given at a dose of 1,500 mg/m2 on days 8 through 12."	2.69	Ifosfamide and gemcitabine: a phase II trial in advanced inoperable non-small cell lung cancer. ( Blatter, J; Chomy, F; Chomy, P; Drings, P; Eberhard, W; Gatzemeier, U; Khayat, D; Manegold, C; Seeber, S; Wilke, HJ, 1998)
"Ifosfamide 4 g/m2 was given for 4 h by intravenous infusion on day 2."	2.69	Phase II study of paclitaxel (Taxol) and ifosfamide (Holoxan) in inoperable non-small-cell lung cancer. ( Thongprasert, S, 1998)
"Megestrol acetate 250 mg PO was administered throughout the duration of chemotherapy."	2.69	A brief intensive cisplatin-based outpatient chemotherapy regimen with filgrastim and megestrol acetate support for advanced non-small cell lung cancer: results of a phase II trial. ( Craffey, M; Dowlati, A; Levitan, N; MacKay, W; McKenney, J; Remick, SC; Tahsildar, H, 1998)
" Four patients were assigned to different dosage levels, and drug toxicity was evaluated for the first 2 cycles."	2.69	Phase I study of a combination of irinotecan and ifosfamide in advanced primary lung cancer. ( Gohara, R; Ichiki, M; Kawayama, T; Kinoshita, M; Mitui, T; Oizumi, K; Okubo, Y; Rikimaru, T, 1999)
"The ifosfamide dose was escalated as follows: 3000 mg/m2 (level 1), 5000 mg/m2 (level 2), 7000 mg/m2 (level 3), 9000 mg/m2 (level 4)."	2.69	A phase I dose escalation study of multicyclic, dose-intensive chemotherapy with peripheral blood stem cell support for small cell lung cancer. ( Arakawa, M; Chou, D; Gejyo, F; Ito, K; Kagamu, H; Sakai, K; Shimbo, T; Suzuki, E; Takahashi, M; Tanaka, H; Tanaka, J; Wakabayashi, M; Yoshizawa, H, 2000)
" The present retrospective analysis assessed two ways of dosing carboplatin: according to body surface area (mg/m2) or to the estimated targeted area under the concentration versus time curve (AUC)."	2.69	A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer. European Lung Cancer Working Party. ( Alexopoulos, CG; Berchier, MC; Bureau, G; Giner, V; Klastersky, J; Koumakis, G; Lafitte, JJ; Lecomte, J; Mommen, P; Ninane, V; Paesmans, M; Sculier, JP; Thiriaux, J; Zacharias, C, 1999)
"The gemcitabine dose was escalated from 500 to 1200 mg/m2 on days 3 and 8 every third week."	2.69	Ifosfamide, vinorelbine and gemcitabine in advanced non-small cell lung cancer. A phase I study. ( De Filippis, S; Guerriero, G; Pompili, P; Rea, S; Recchia, F; Rosselli, M, 1999)
"To determine the population pharmacokinetic (PK) parameters of doxorubicin (Dox), etoposide (Eto) and ifosfamide (Ifo) in small cell lung cancer (SCLC) patients, to assess the potential relationship between those parameters and to estimate the impact of individual morphological and biological covariates on patients' PK parameters."	2.69	Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study. ( Ardiet, C; Boissel, JP; Court-Fortune, I; Freyer, G; Girard, P; Ligneau, B; Rebattu, P; Riou, R; Souquet, PJ; Tranchand, B; Trillet-Lenoir, V, 2000)
" Our trial failed to demonstrate a significant improvement in response or survival when patients with metastatic NSCLC were treated, in addition to ifosfamide and mitomycin, by combination of moderate dosages of cisplatin and carboplatin instead of moderate dosage of cisplatin alone."	2.69	Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer. ( Alexopoulos, CG; Baumöhl, J; Berghmans, T; Florin, MC; Klastersky, J; Koumakis, G; Lafitte, JJ; Mommen, P; Ninane, V; Paesmans, M; Schmerber, J; Sculier, JP; Thiriaux, J; Zacharias, C, 2000)
"Paclitaxel dose levels were 135, 170, 200, 250, and 300 mg/m2."	2.68	Paclitaxel and ifosfamide: a multicenter phase I study in advanced non-small cell lung cancer. ( Bitran, JD; Drinkard, LC; Golomb, HM; Hoffman, PC; Krauss, SA; Masters, GA; Samuels, BL; Vokes, EE; Watson, S, 1995)
" The dosage of paclitaxel was escalated from 75 to 225 mg/m2."	2.68	A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer. ( Carey, RW; Elias, AD; Grossbard, ML; Jacobs, C; Jauss, S; Kwiatkowski, DJ; Lynch, TJ; Shulman, LN; Strauss, GM; Sugarbaker, DJ, 1995)
"The early stages of bronchial carcinoma are still a domain of operative treatment."	2.68	[Neoadjuvant radiochemotherapy in locally advanced non-small cell bronchial carcinoma. Initial results of a prospective multicenter study]. ( Klinke, F; Micke, O; Rübe, C; von Eiff, M; Wagner, W; Willich, N, 1995)
"Ifosfamide is a chiral pro-drug which is administered clinically in its racemic form."	2.68	Pharmacokinetics of ifosfamide and its enantiomers following a single 1 h intravenous infusion of the racemate in patients with small cell lung carcinoma. ( Chrystyn, H; Corlett, SA; Parker, D, 1995)
"Ifosfamide was therefore decreased to 1."	2.68	Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer. ( Drinkard, LC; Golomb, HM; Hoffman, PC; Masters, GA; Samuels, BL; Vokes, EE; Watson, S, 1996)
" MIP regimen was permanently suspended in 14 patients because of toxic events."	2.68	Efficacy and toxicity of mitomycin, ifosfamide, and cisplatin (MIP) in patients with inoperable non-small cell lung cancer. ( Baud, M; Bedin, A; Chouaid, C; Febvre, M; Lebeau, B; Urban, T, 1996)
"Ifosfamide was administered at a dose of 1."	2.68	Ifosfamide plus paclitaxel in advanced non-small-cell lung cancer: a phase I study. ( Drinkard, LC; Golomb, HM; Hoffman, PC; Krauss, SA; Masters, GA; Samuels, BL; Vokes, EE, 1996)
"The addition of IFN-alpha to induction CT appears to confer a survival benefit to SCLC patients but optimal dosing schedule has yet to be defined."	2.68	Interferon alpha-2a and combined chemotherapy as first line treatment in SCLC patients: a randomized trial. ( Charitopoulos, K; Dimitriadis, K; Economides, D; Maglaveras, N; Papagiannis, A; Vamvalis, C; Zarogoulidis, K; Ziogas, E, 1996)
"Phlebitis was observed in 15 of 30 patients (50%) who did not have central implantable venous systems."	2.68	Ifosfamide and vinorelbine as first-line chemotherapy for advanced non-small cell lung carcinoma. ( Amato, S; Barbieri, M; Cuevas, M; Dominguez, M; Lacava, J; Langhi, M; Leone, B; Machiavelli, M; Ortiz, E; Perez, J; Rodriguez, R; Romero Acuña, J; Romero Acuña, L; Romero, A; Sabatini, C; Salvadori, M; Vallejo, C, 1996)
" Both have a dose-response relationship."	2.68	Phase II study of a closely spaced ifosfamide--cisplatin schedule with the addition of G-CSF in advanced non-small-cell lung cancer and malignant melanoma. ( de Wit, R; Planting, AS; Stoter, G; van der Burg, ME; Verweij, J, 1996)
"The ongoing phase I study reported here sought to determine the maximum tolerated doses of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin when given at specific times in combination with ifosfamide, mesna, and filgrastim."	2.68	Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results. ( Palackdharry, CS, 1997)
"Gemcitabine was administered at a dose of 1,000 mg/m2 on days 1, 8, and 15 followed by a 1-week rest, while ifosfamide was given at a dose of 1,500 mg/m2 on day 8 and days 9 through 12."	2.68	A phase II trial of gemcitabine and ifosfamide in non-small cell lung cancer. ( Blatter, J; Chomy, F; Chomy, P; Drings, P; Eberhard, W; Gatzemeier, U; Khayat, D; Manegold, C; Seeber, S; Wilke, HJ, 1997)
" The study design and dosing schedule are discussed in this report."	2.68	Paclitaxel/carboplatin plus ifosfamide in non-small cell lung cancer. ( Golomb, HM; Hoffman, PC; Masters, G; Mauer, AM; Vokes, EE; Watson, S, 1997)
"We have treated 26 consecutive chemotherapy-naive patients with stage IIIB/IV non-small cell lung cancer with an innovative regimen based on a 1-hour infusion of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) 125 to 250 mg/m2, ifosfamide 3 g/m2 (with mesna), and carboplatin dosed to an area under the concentration-time curve of 5, every 21 days for a total of six cycles in responding or stabilized patients."	2.68	Paclitaxel, ifosfamide, and carboplatin for the treatment of stages IIIB and IV non-small cell lung cancer: preliminary results. ( Alghisi, A; Bozzola, G; Marini, G; Meriggi, F; Mutti, S; Pascarella, A; Rizzi, A; Zaniboni, A, 1997)
"Paclitaxel was escalated from 75 to 225 mg/m2 in 25-mg/m2 increments."	2.68	Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis. ( Carey, RW; Elias, AD; Grossbard, ML; Herbst, R; Jacobs, C; Kwiatkowski, DJ; Leong, T; Lynch, C; Lynch, TJ; Skarin, AT; Strauss, GM, 1997)
"Levels of depression were lower and showed little change."	2.67	A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). II: Quality of life. Medical Research Council Lung Cancer Working Party. ( Bleehen, NM; Girling, DJ; Machin, D; Stephens, RJ, 1993)
"Ifosfamide was infused at the dose of 2 g/m2 over a 4-hour bolus infusion, followed by 2-g/m2 24-hour continuous infusions of ifosfamide, for a total of 14 or 18 g/m2 (6-8 days)."	2.67	Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. ( Eckardt, J; Eilber, F; Forscher, C; Fu, YS; Holmes, C; Lowenbraun, S; Rosen, G, 1994)
"The etoposide dose was escalated, with six patients receiving 300 mg/m2 total dose (level 1), six receiving 600 mg/m2 (level 2), three receiving 900 mg/m2 (level 3), and five receiving 1,200 mg/m2 (level 4)."	2.67	Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer. ( Comis, R; Haas, N; Kilpatrick, D; Krigel, RL; Langer, C; Padavic, K; Palackdharry, CS, 1994)
"Verapamil 480 mg day-1 was given for 3 days starting 24 h prior to chemotherapy which consisted of bolus vindesine 7 mg followed by ifosfamide/mesna 5 g m-2 over 24 h, followed by mesna alone for a further 8 h."	2.67	Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study. ( Cantwell, BM; Corris, PA; Harris, AL; Millward, MJ; Munro, NC; Robinson, A, 1993)
"Ifosfamide has shown promising single-agent activity in non-small cell lung cancer."	2.67	Phase II study of cisplatin, ifosfamide, and etoposide combination for advanced non-small cell lung cancer: final report. ( Dhingra, HH; Greenberg, J; Hong, WK; Lee, JS; Shirinian, M, 1992)
"Oral etoposide was given on days 1-5, 15-19, and 29-33."	2.67	A randomised study of intravenous bolus versus continuous infusion of ifosfamide and doxorubicin with oral etoposide for small-cell lung cancer. ( Anderson, H; Prendiville, J; Radford, JA; Swindell, R; Thatcher, N, 1991)
"Ifosfamide was administered by intravenous drip infusion at a daily dose of 2 g/m2 for 5 consecutive days, and mesna was intravenously administered at 20% of the ifosfamide dose, three times daily for 5 consecutive days."	2.67	Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders. ( Fukuoka, M; Furuse, K; Ikegami, H; Kawahara, M; Kodama, N; Masuda, N; Nakamura, S; Negoro, S; Nishio, H; Ohnoshi, T, 1991)
"Thirty six patients with advanced solid tumors (24 lung: 3 oat-cell, 14 squamous, 7 adenocarcinomas, 3 soft tissue sarcomas, 6 breast carcinomas; 1 seminoma; 2 ovarian adenocarcinomas) entered a phase II study of high-dose ifosfamide (IF) administered in combination with the uroprotective agent sodium 2-mercapto-ethane-sulfonate (Mesna)."	2.65	Phase II study of ifosfamide combined with Mesna uroprotection in advanced non-small-cell lung carcinoma and other solid tumors. ( Brema, F; Cinquegrana, A; Nobile, MT; Rosso, R; Santi, L, 1984)
" The major dose-limiting toxic effect of CIA was leukopenia."	2.64	Protection against chemotherapy toxicity by IV hyperalimentation. ( Bodey, GP; Copeland, EW; Dudrick, SJ; Freireich, EJ; Issell, BF; Valdivieso, M; Zaren, HA, 1978)
" A daily dosage of 50 to 60 mg/kg ifosfamide on 5 consecutive days produced the best results."	2.64	Evaluation of a cooperative clinical study of the cytostatic agent ifosfamide. ( Brock, N; Burkert, H; Fichtner, E; Schnitker, J, 1976)
"Extraosseous Ewing sarcoma is a rare, poorly differentiated round-cell tumour that is part of the Ewing sarcoma family of tumours."	2.61	Primary Ewing sarcoma of the larynx with distant metastasis: a case report and review of the literature. ( Khalifeh, I; Maroun, CA; Moukarbel, RV; Tfayli, A, 2019)
"Chemotherapy for treatment of osteosarcoma was demonstrated to be effective in eradicating primary tumor and pulmonary metastases in the mid-twentieth century."	2.50	Historical perspective on the introduction and use of chemotherapy for the treatment of osteosarcoma. ( Jaffe, N, 2014)
" We therefore investigated the therapeutic efficacy of STI571, alone or combined with chemotherapy, in human SCLC cells or tumors xenografted into nude mice."	2.43	In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy. ( de Cremoux, P; Decaudin, D; Fréneaux, P; Judde, JG; Livartowski, A; Nemati, F; Pouillart, P; Poupon, MF; Sastre, X; Tran-Perennou, C, 2005)
"Synovial sarcoma is a malignant soft-tissue neoplasm, usually arising in close association with the joints and generally carrying a poor prognosis."	2.43	Bilateral metastatic renal synovial sarcoma. ( Matin, SF; Pollock, RE; Stage, AC, 2005)
"Myxoid liposarcoma has a relatively good prognosis but tends to recur locally."	2.43	Myxoid liposarcoma metastatic to the thyroid gland: a case report and literature review. ( Clarke, PM; Sandison, A; Tysome, JR, 2006)
"Ifosfamide is an old drug still considered an effective cytostatic agent in the treatment of NSCLC."	2.42	Ifosfamide in non-small cell lung cancer. ( Boni, C; Zanelli, F, 2003)
"Brain metastases are rare in the natural history of Wilms tumor."	2.41	Brain metastases in Wilms' tumor: case report and literature review. ( Grimard, L; Halton, JM; Hsu, E; MacRae, R; Nizalik, E, 2002)
"Ifosfamide has been in use for several decades and is generally considered to be one of the most effective drugs for the treatment of non-small cell lung cancer (NSCLC)."	2.40	Ifosfamide and docetaxel in non-small cell lung cancer. ( Büchholz, E; Drings, P; Manegold, C, 1998)
"Ifosfamide has been combined with gemcitabine in a phase I/II study."	2.40	Combination studies with gemcitabine in the treatment of non-small-cell lung cancer. ( Steward, WP, 1998)
"Gemcitabine has a mild toxicity profile that allows it to be combined easily in triplet combinations with other doublets."	2.40	Triplet chemotherapy with gemcitabine, a platinum, and a third agent in the treatment of advanced non-small cell lung cancer. ( Bunn, PA, 1999)
"Ifosfamide has been used in combination with several drugs including cisplatin, giving rise to multiple doublets and triplets including the ifosfamide-cisplatin-mitomycin regimen (Cullen's MIC regimen) that has been commonly used in Europe."	2.40	Ifosfamide in non-small-cell lung cancer. ( Balaña, C; Martin, C; Rosell, R, 1999)
"Paclitaxel has been used in combination with several other nonplatinum agents for the treatment of NSCLC."	2.40	Single-agent paclitaxel and paclitaxel/non-platinum combination therapy in advanced non-small cell lung cancer. ( Langer, CJ; Socinski, MA, 1999)
"Ifosfamide has been found to have antineoplastic activity in a variety of solid tumors."	2.39	The role of ifosfamide in germ cell tumors and small cell lung cancer. ( Nichols, CR, 1995)
"Ifosfamide is an analogue of cyclophosphamide that is active against a variety of solid tumors, including non-small cell lung cancer."	2.39	Ifosfamide in non-small cell lung cancer. ( Johnson, DH, 1996)
"Ifosfamide has the broad range of clinical activity, but its ultimate role as part of initial therapy remains to be discerned."	2.38	Clinical trials with ifosfamide: the Indiana University experience. ( Einhorn, LH; Loehrer, PJ; Nichols, CR; Williams, SD, 1992)
" The stability of ifosfamide and its high bioavailability have allowed its use in chronic, 7-day ambulatory IV infusions, with decreased toxicity and hospitalization."	2.38	Novel approaches with ifosfamide in small cell lung cancer. ( Cerny, T; De Campos, E; Lind, M; Thatcher, N, 1992)
"The role of chemotherapy in the treatment of myxofibrosarcoma is unclear."	1.56	Complete remission of a case of high-grade myxofibrosarcoma with lung metastases after modified MAID regimen chemotherapy. ( Cui, Y; Pan, Y; Shi, X, 2020)
"NUT carcinoma is an extremely rare disease and yet extremely aggressive with 2-year survival of only approximately 19% and median survival of 6 to 9 months."	1.56	Durable Complete Remission of PD-L1 Positive NUT Carcinoma Treated With Concurrent Chemotherapy and Radiation. ( Chang, JS; Pan, M, 2020)
"Malignant phyllodes tumors are rare breast neoplasms that are associated with a 6."	1.51	Complete remission of giant malignant phyllodes tumor with lung metastasis: A case report. ( Jung, JH; Kim, WW; Lee, J; Lee, JW; Lee, SJ; Moon, SH; Park, HY, 2019)
"Ameloblastoma is generally characterized as a benign tumor originating in odontogenic epithelium."	1.51	MAID chemotherapy regimen as a treatment strategy for metastatic malignant ameloblastoma: A case report. ( Li, D; Liu, Y; Qiao, L; Sun, M; Wang, L; Xu, S, 2019)
"Considering the physical condition of patient, the patient underwent surgical resection of the right lung lesion after receiving endostar combined with chemotherapy and maintained endostar alone for 47 cycles."	1.46	Endostar combined with chemotherapy in a pediatric osteosarcoma with pulmonary metastasis and malignant pleural effusion: A case report. ( Dong, Y; Jiang, S; Wang, G, 2017)
"Patients with bones or brain metastases were treated with palliative radiotherapy only or combined with Doxorubicin."	1.43	Treatment of Patients with Distant Metastases from Phyllodes Tumor of the Breast. ( Blecharz, P; Jakubowicz, J; Kulpa, J; Mituś, JW; Reinfuss, M; Walasek, T, 2016)
" The aim of this study was to assess the efficacy and safety of ifosfamide in combination with carboplatin and etoposide (ICE) in previously untreated patients with SCLC."	1.42	Efficacy and safety of ifosfamide in combination with carboplatin and etoposide in small cell lung cancer. ( Koo, DH; Lee, HS; Lee, SS; Lee, YG; Lim, SY; Nam, H; Oh, S; Song, JU, 2015)
" A partial radiological response was achieved; dosage was reduced to 1."	1.40	Response to trabectedin in a patient with advanced synovial sarcoma with lung metastases. ( Basso, U; Maruzzo, M; Montesco, MC; Rastrelli, M; Roma, A; Zanardi, E, 2014)
"Pediatr Blood Cancer 2015;62:274-278."	1.40	( Adiguzel, R; Andreana, PR; Arslan, Z; Ates, M; Bemis, T; Bercovitch, LG; Bögli, S; Boucherez, J; Boudouf, S; Briat, JF; Brown, BM; Busemann, A; Buters, J; Byers, JS; Cairo, MS; Carrier, F; Chalmers, JJ; Chang, E; Chen, J; Chen, Y; Christenson, MK; Cielecka-Piontek, J; Cole, PA; Cooper, BS; Davis, PH; De Silva, RA; Decato, S; DeFries, RS; Demir, V; Denic, A; Deserno, M; Dickey, AM; Diss, E; Eberlein, B; Eyerich, S; Faluvegi, G; Farlow, MR; Fletcher, JW; Francetic, T; Furlan, L; Garbacki, P; Gartung, A; Garvin, JH; Gates, L; Gaymard, F; Ghetti, B; Gibson, MP; Griffin, RG; Hamed, M; Hammad, LA; Hammond, GB; Han, J; Hann, R; Hao, N; Harrison, LA; Heidecke, CD; Hutchins, GD; Inlow, M; Irmer, H; Jani, P; Jara-Cavieres, A; Jawadi, H; Jiang, Q; Jiang, Y; Kameda, T; Keeler, EG; Kim, H; Kim, R; Kim, S; Kinney, PL; Krause, A; Kumar, V; Kwok, Y; Lam, T; Lanni, F; Le May, M; Lee, A; Lee, JF; Lee, MJ; Leontyev, IV; Li, Q; Li, X; Liu, J; Liu, NK; Lominadze, D; Lösche, M; Lu, QB; Lu, Y; Lu, Z; Mach, H; Madsen, E; Marletta, M; Marlier, ME; McDonald, BC; McKay, IS; Mckenzie, CL; Mecozzi, S; Menges, P; Meyers, D; Michaelis, VK; Montooth, KL; Moore, LR; Morgan, JK; Morris, E; Movahed, M; Nalabothula, N; Narayanan, S; Nguyen, D; Nho, K; Oken, B; Ong, TC; Osborne, LS; Paczkowska, M; Park, EK; Pennino, D; Peters, S; Potluri, LP; Qin, C; Radhakrishnan, K; Randerson, JT; Rantanen, J; Reyt, G; Ring, J; Risacher, SL; Rodriguez, M; Saykin, AJ; Schmidt-Weber, CB; Sengelaub, DR; Shatters, RG; Shen, L; Shen, V; Shindell, DT; Stuchebrukhov, AA; Swaminathan, S; Takahashi, K; Talaczyńska, A; Tallman, EF; Tan, C; Terry, SF; Trabbic, KR; Trease, AJ; Tretter, C; Uitto, J; Váradi, A; von Bernstorff, W; Voulgarakis, A; Wagenhofer, M; Wahbeh, H; Wang, EN; Wang, X; Wells, RJ; West, JD; Williams, PS; Wolff, JE; Wootla, B; Xu, B; Xu, XM; Yoder, KK; Zalewski, P; Zan, GH; Zborowski, M; Zhang, HH; Zhang, W; Zhao, J; Zoecklein, L, 2014)
"Alveolar soft part sarcomas are rarely seen and highly malignant tumors, and the prognosis of stage IV ASPS is poor."	1.38	[Treatment and prognosis of stage IV alveolar soft part sarcoma]. ( Yang, Y; Zhao, J, 2012)
" No significant dose-response relationship was found in terms of LRC."	1.37	Sequential or concomitant chemotherapy in limited stage small-cell lung cancer. ( Anchisi, S; Bieri, S; Elhfidh, M; Khanfir, K; Matzinger, O; Mirimanoff, RO; Ozsahin, M; Zouhair, A, 2011)
"Breast stromal sarcoma is very rare, accounting for less than 1% of mammary neoplasms, and the treatment strategy is not well established, especially regarding chemotherapy."	1.37	Stromal sarcoma of the breast with lung metastases showing a clinical complete response to doxorubicin plus ifosfamide treatment: report of a case. ( Inoue, K; Iwase, H; Kuriwaki, K; Sueta, A; Yamamoto, Y, 2011)
"We present a case of pleomorphic malignant fibrous histiocytoma arising from the left forearm in a 45-year-old man who had undergone resection and radiotherapy for a tumor 3 years previously."	1.35	Pleomorphic malignant fibrous histiocytoma: response of bone, lung, and brain metastases to chemotherapy. ( Hoshi, M; Ieguchi, M; Takami, M, 2008)
"A 30-year-old man was diagnosed with testicular cancer, and underwent a radical orchiectomy."	1.35	[A case of recurrent metastatic testicular cancer, successfully treated with paclitaxel, ifomide and cisplatin]. ( Egawa, S; Hatano, T; Ito, H; Kishimoto, K; Tomita, M; Wada, T; Yanada, S, 2008)
"From 1979 to 2002, 27 patients with Ewing's sarcoma (20) or PNET (7) were treated."	1.34	Ewing's sarcoma and primitive neuroectodermal tumour in adults: single-centre experience in The Netherlands. ( Boven, E; Meijer, OW; Smorenburg, CH; van Groeningen, CJ; Visser, M, 2007)
"Paclitaxel (175 mg/m(2)) was administered on day 1 and ifosfamide (2500 mg/m(2)) on day 1-2 every 3 weeks."	1.34	Combination chemotherapy with paclitaxel and ifosfamide as the third-line regimen in patients with heavily pretreated small cell lung cancer. ( Ahn, JS; Ahn, MJ; Hong, YS; Hwang, IG; Kang, WK; Lee, J; Lee, SC; Lim, H; Park, BB; Park, JO; Park, K; Park, S, 2007)
"The response of adult soft tissue sarcoma (STS) to chemotherapy is uncertain."	1.34	[Responses of 109 adult soft tissue sarcoma patients to chemotherapy]. ( Guan, ZZ; Huang, HQ; Jiang, WQ; Li, FH; Lin, TY; Luo, HY; Qiu, MZ; Sun, XF; Wang, F; Wang, SS; Xu, F; Xu, GC; Xu, RH, 2007)
"Angiosarcomas are rare soft tissue malignancies."	1.33	Metastatic angiosarcoma of the kidney: a case report with treatment approach and review of the literature. ( Bearz, A; Berretta, M; Berretta, S; Brollo, A; Buonadonna, A; Canzonieri, V; Frustaci, S; Morra, A; Rupolo, M; Tirelli, U, 2006)
" The purpose of the study was to determine the optimal dosage and the maximal tolerated dose (MTD) of a specified schedule of gemcitabine and ifosfamide."	1.33	Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancer. ( Aschroft, L; Baka, S; Blackhall, F; Buchholz, E; Lorigan, P; Manegold, C; Nagel, S; Schott-von-Römer, K; Thatcher, N, 2006)
"Synovial sarcoma is an extremely rare primary pulmonary tumor whose description is based on a limited number of cases."	1.32	[Primary pulmonary synovial sarcoma: a report and diagnosis of 2 cases]. ( Baldo Padró, X; Bernadó Turmo, L; Haro Estarriol, M; Rubio Goday, M; Sebastián Quetglas, F; Viñas Villaró, G, 2003)
"Spinal cord compression has also been rarely reported in all age groups."	1.32	Spinal cord compression and lung metastasis of Wilms' tumor in a pregnant adolescent. ( Akansel, G; Arisoy, AE; Calişkan, M; Corapcioglu, F; Dillioğlugil, O; Sarper, N, 2004)
"The response rate in brain metastases was 50."	1.31	Combination chemotherapy of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with brain metastases from non-small cell lung cancer. ( Fujita, A; Fukuoka, S; Sekine, K; Tagaki, S; Takabatake, H, 2000)
"The aim of this study was to develop a population pharmacokinetic model that could describe the pharmacokinetics of ifosfamide."	1.31	Population pharmacokinetics of ifosfamide and its 2- and 3-dechloroethylated and 4-hydroxylated metabolites in resistant small-cell lung cancer patients. ( Beijnen, JH; Groen, HJ; Huitema, AD; Kerbusch, T; Mathĵt, RA; vanPutten, JW, 2001)
" Similar dose-response curves were found for both metabolites."	1.30	Ifosfamide cytotoxicity on human tumor and renal cells: role of chloroacetaldehyde in comparison to 4-hydroxyifosfamide. ( Brüggemann, SK; Kisro, J; Wagner, T, 1997)
"The role and value of chemotherapy for soft tissue sarcomas remain unclear."	1.30	[Chemotherapy for pulmonary metastases of soft tissue sarcoma]. ( Kito, M; Umeda, T, 1998)
"But pulmonary hemorrhage and respiratory failure resulted in her death 7 months after initial diagnosis."	1.30	Treatment of primary pure angiosarcoma of ovary with multiple lung metastases: a case report. ( Chao, KC; Juang, CM; Lai, CZ; Lu, CJ; Twu, NF; Yeng, MS, 1999)
" These results compare favourably with other combined modality studies, using multiple radiotherapy fractions with cisplatin-based combinations and dosage reduction for patients staged in more anatomical detail."	1.29	Therapy for small cell lung cancer using carboplatin, ifosfamide, etoposide (without dose reduction), mid-cycle vincristine with thoracic and cranial irradiation. ( Burt, P; Hicks, F; Leahy, B; Lorigan, P; Prendiville, J; Stout, R; Thatcher, N, 1994)
"Ifosfamide was administered at the daily dose of 1200 mg/m2/24 h."	1.29	[Peri-operative chemotherapy during resection of pulmonary metastases of sarcoma]. ( Azorin, JF; Delepine, G; Delepine, N; Destable, MD; Pocard, M; Tremblay, B, 1994)
" The dosage of IEP in this study caused moderate toxicity."	1.29	Ifosfamide, epirubicin and cisplatin (IEP): another active combination for small cell lung cancer (SCLC). ( Jiamsriponges, K; Thongprasert, S, 1993)
"A case of malignant fibrous histiocytoma (MFH) of jejunal origin with brain and lung metastases was treated by jejunal resection."	1.29	[A case of malignant fibrous histiocytoma of jejunal origin with marked response to cisplatin, ifosfamide and adriamycin]. ( Fujita, A; Isai, H; Kondo, M; Minase, T; Sekine, K; Tagaki, S, 1993)
" Moreover, a dose-response relationship was detectable: 1/6 patients without lung irradiation vs."	1.29	Lung irradiation for Ewing's sarcoma with pulmonary metastases at diagnosis: results of the CESS-studies. ( Dunst, J; Jürgens, H; Paulussen, M, 1993)
" As compared with the values obtained on day 1, on day 5 the terminal half-life and AUC values determined for IF were reduced by 30% (6."	1.29	Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. ( Kurowski, V; Wagner, T, 1993)
"Ifosfamide has shown promising single-agent activity in non-small cell lung cancer (NSCLC)."	1.28	Phase II study of cisplatin, ifosfamide with mesna, and etoposide (PIE) chemotherapy for advanced non-small cell lung cancer. ( Dhingra, HH; Greenberg, J; Hong, WK; Lee, JS; Shirinian, M, 1992)
"The authors report a case of pulmonary squamous cell carcinoma which occurred after chemotherapy of non-Hodgkin's lymphoma (NHL)."	1.28	[Elderly non-Hodgkin's lymphoma presenting with pulmonary squamous cell carcinoma as a complication of chemotherapy for malignant lymphoma]. ( Annoh, S; Arai, N; Kaneko, H; Shirai, T; Tsukahara, T; Umeda, M, 1992)
"Cerebral metastases occurred in 20% of all patients and was the apparent sole site of relapse in 11% of the CR patients."	1.28	Intensive therapy for small-cell lung cancer using carboplatin alternating with cisplatin, ifosfamide, etoposide, mid-cycle vincristine, and radiotherapy. ( Burt, P; Prendiville, J; Radford, J; Ranson, M; Steward, W; Stout, R; Thatcher, N, 1991)
"Ifosfamide is a newly available analog of cyclophosphamide in the oxazaphosphorine drug class."	1.28	Ifosfamide vs cyclophosphamide in cancer therapy. ( Weiss, RB, 1991)
"Thirty-one patients with inoperable squamous cell carcinoma of the lung were treated with a combination of cis-platin (CDDP, 100 mg/m2 day 1), ifosfamide (IFX, 2 g/m2 day 1, 2, 3; with mesna) and vindesine (VDS, 3 mg/m2 day 1)."	1.28	[Cisplatin, ifosfamide and vindesine in the chemotherapy of squamous cell carcinoma of the lung]. ( Asakawa, M; Fujita, A; Honda, R; Inoue, Y; Nakajima, S; Sasaki, H; Sekine, K; Suzuki, A, 1991)
" A positive correlation was found between the elimination half-life of ifosfamide and age (r = 0."	1.28	The effect of age on the pharmacokinetics of ifosfamide. ( Cerny, T; Lind, MJ; Margison, JM; Thatcher, N; Wilkinson, PM, 1990)
" Treatment was repeated every 3 weeks for a maximum of six courses and no dosage reductions were allowed."	1.28	Ifosfamide, doxorubicin and etoposide in small cell lung cancer patients with poor prognosis. ( Bronchud, MH; Kamthan, AG; Lind, MJ; Ranson, MR; Steward, WP; Stout, R; Thatcher, N, 1990)
"The course of 72 patients (36 with squamous carcinoma, 25 with adenocarcinoma, two with alveolar-cell carcinoma and nine with large-cell carcinoma) could be evaluated."	1.27	[Chemotherapy of the non-small cell carcinoma of the lung with ifosfamide and cisplatin]. ( Abel, U; Dirks, HP; Drings, P; Grimm, V; Heinrich, S; Kleckow, M; Manke, HG; Queisser, W; Stiefel, P, 1984)
" The collected experience emphasizes the many individual variables encountered in clinical practice complicating the effort of correlating pharmacokinetic data with clinical results."	1.27	Pharmacokinetic studies in lung cancer patients. ( Cattaneo, MT; Piazza, E; Varini, M, 1984)
"The most frequent histology was squamous cell carcinoma found in 20 patients."	1.27	[Chemotherapy with mitomycin C, vindesine and ifosfamide in the treatment of inoperable non-small cell bronchial carcinoma]. ( Gatzemeier, U; Hossfeld, DK; Radenbach, D; Zschaber, R, 1985)
" IFN-alpha nl alone at this dosage was shown to have some cytotoxic activity."	1.27	Augmentation of cytotoxicity of chemotherapy by human alpha-interferons in human non-small cell lung cancer xenografts. ( Balkwill, FR; Carmichael, J; Fergusson, RJ; Smyth, JF; Wolf, CR, 1986)
"Ifosfamide at 5 g/m2 was given as a bolus to 48 patients with advanced progressing non-small cell lung cancer."	1.27	Ifosfamide by bolus as treatment for advanced non-small cell lung cancer. ( Anderson, H; Hilton, A; Rahman, A; Smith, DB; Steward, WP; Thatcher, N; Webb, K, 1986)
"The etoposide combination was tolerated better."	1.27	Experience with ifosfamide combinations (etoposide or DDP) in non-small cell lung cancer. ( Abel, U; Bülzebruck, H; Drings, P; Kleckow, M; Manke, HG; Stiefel, P, 1986)
"Ifosfamide and mesna were administered to 77 patients with advanced malignancies."	1.27	Prediction of ifosfamide/mesna associated encephalopathy. ( Blackledge, G; Blake, AE; Honigsberger, L; Kelly, KA; Meanwell, CA, 1986)
" There was a proportionate increase in the AUC for the 5-g oral dose, indicating 100% bioavailability at all three dose levels."	1.27	Bioavailability of ifosfamide in patients with bronchial carcinoma. ( Cerny, T; Margison, JM; Thatcher, N; Wilkinson, PM, 1986)
"Ifosfamide (Holoxan) has an effect as a single drug on testicular carcinoma and shows synergism with cisplatinum in mice."	1.26	The value of ifosfamide in the polychemotherapy of metastasized testicular cancer pretreated with chemotherapy. ( Clemm, C; Hartenstein, R; Wilmanns, W, 1982)
"Oral ifosfamide therapy was determined to be feasible, and further studies are justified to assess the pharmacokinetics of the optimum dosage and scheduling regimens."	1.26	The bioavailability of oral and intravenous ifosfamide in the treatment of bronchogenic carcinoma. ( McNiel, NO; Morgan, LR, 1981)
"Ifosfamide was administered to 21 patients with recurrent or disseminated lung cancer at a dose of 4."	1.26	Ifosfamide in the treatment of recurrent or disseminated lung cancer: a phase II study of two dose schedules. ( Costanzi, JJ; Gagliano, R; Hokanson, JA; Loukas, D; Panettiere, FJ, 1978)
"153 patients with inoperable malignant tumors were treated by the so-called synchronization therapy with vincristine and ifosfamide."	1.26	[Clinical experiences with holoxan within the framework of sequential combination therapy (author's transl)]. ( Hartwich, G; Lutz, H; Neidhardt, B, 1978)
"12 patients with extensive metastases of malignant testicular tumors and 5 other patients with other rapidly growing metastasizing tumors were treated."	1.25	[Cytostatic therapy of tumors under conditions of partial synchronisation with particular reference to malignant tumors of the testicle (author's transl)]. ( Jonas, U; Körner, F; Lund, S, 1975)

Research

Studies (737)

Authors

Clinical Trials (26)

Trial Overview

Trial Outcomes

Overall Survival Rate

Progression Free Survival Rate

Timeframe	Studies, this research(%)	All Research%
pre-1990	120 (16.28)	18.7374
1990's	312 (42.33)	18.2507
2000's	216 (29.31)	29.6817
2010's	80 (10.85)	24.3611
2020's	9 (1.22)	2.80

Authors	Studies
Miao, L	1
Ma, ST	1
Jiang, X	1
Zhang, HH	2
Wang, YM	1
Li, M	1
Conforti, F	1
Pala, L	1
Vivanet, G	1
Corti, C	1
Catania, C	1
Maiettini, D	1
Varano, G	1
Di Venosa, B	1
Curigliano, G	2
Salvini, P	1
Berardi, R	1
Ballatore, Z	1
De Pas, TM	1
Miyoshi, AI	1
Ueda, Y	1
Kurita, T	1
Kimura, T	1
Yoshino, K	1
Hosomi, T	1
Shibasaki, N	1
Otsuka, H	1
Uketa, S	1
Makino, Y	1
Shichiri, Y	1
Maroun, CA	1
Khalifeh, I	1
Tfayli, A	1
Moukarbel, RV	1
Cui, Y	1
Pan, Y	1
Shi, X	1
Inoue, S	1
Hirai, S	2
Katayama, T	1
Benkhaled, S	1
Mané, M	1
Jungels, C	1
Shumelinsky, F	1
Aubain, NS	1
Van Gestel, D	1
Pan, M	1
Chang, JS	1
Hui, C	1
Shin, DH	1
Wakeling, A	1
Donaldson, SS	1
Hazard, FK	1
Rangaswami, A	1
Hiniker, SM	1
Pannu, AK	1
Sharma, N	1
Young, RJ	1
Litière, S	1
Lia, M	1
Hogendoorn, PCW	1
Fisher, C	1
Mechtersheimer, G	1
Daugaard, S	1
Sciot, R	1
Collin, F	1
Messiou, C	1
Grünwald, V	1
Gronchi, A	1
van der Graaf, W	1
Wardelmann, E	1
Judson, I	1
Meazza, C	2
Cefalo, G	1
Massimino, M	1
Daolio, P	2
Pastorino, U	2
Scanagatta, P	2
Morosi, C	1
Podda, M	3
Ferrari, A	3
Terenziani, M	1
Spreafico, F	1
Casanova, M	2
Parafioriti, A	1
Collini, P	2
Gandola, L	2
Bastoni, S	1
Biassoni, V	1
Schiavello, E	1
Chiaravalli, S	1
Puma, N	1
Bergamaschi, L	1
Luksch, R	2
Tanaka, I	1
Kawada, K	1
Morise, M	1
Hase, T	1
Hayashi, H	2
Sokai, A	1
Fukatsu, A	1
Kondo, M	2
Nomura, F	1
Hasegawa, Y	1
Jiang, S	1
Wang, G	1
Dong, Y	1
Carden, MA	1
Perdahl-Wallace, E	1
Greenberg, J	3
McCarty, JM	1
Lee, J	3
Jung, HA	1
Kim, Y	2
Choi, S	1
Han, J	2
Choi, YL	1
Lee, SH	1
Ahn, JS	2
Park, K	4
Sun, JM	1
Tatenuma, T	1
Mizuno, N	1
Jikuya, R	1
Hashizume, A	1
Yasui, M	1
Umemoto, S	1
Kawai, M	1
Hiruma, T	1
Kishida, T	1
Jiang, L	1
Xu, X	1
Davies, H	1
Shi, K	1
Moon, SH	1
Jung, JH	1
Kim, WW	1
Park, HY	1
Lee, JW	1
Lee, SJ	1
Li, D	1
Xu, S	3
Sun, M	1
Qiao, L	1
Wang, L	1
Liu, Y	1
Yamamoto, Y	3
Tsukiyama, I	1
Nii, S	1
Harada, R	1
Watanabe, K	2
Yabushita, H	1
Wakatsuki, A	1
Saito, H	4
Hasegawa, T	1
Tiseo, M	2
Bordi, P	1
Bortesi, B	1
Boni, L	4
Boni, C	7
Baldini, E	9
Grossi, F	2
Recchia, F	4
Zanelli, F	4
Fontanini, G	1
Naldi, N	1
Campanini, N	1
Azzoni, C	1
Bordi, C	1
Ardizzoni, A	10
Choeyprasert, W	1
Natesirinilkul, R	1
Charoenkwan, P	1
Sittipreechacharn, S	1
Johnson, K	1
Notrica, DM	1
Carpentieri, D	1
Jaroszewski, D	1
Henry, MM	1
Al-Hader, AA	1
Jain, A	1
Al-Nasrallah, N	1
Einhorn, LH	9
Koufos, N	1
Michailidou, D	1
Xynos, ID	1
Tomos, P	1
Athanasiadou, K	1
Kosmas, C	6
Tsavaris, N	3
Ozdemir, O	1
Ozdemir, P	1
Veral, A	1
Uluer, H	1
Ozhan, MH	1
Berghmans, T	13
Lafitte, JJ	14
Scherpereel, A	5
Paesmans, M	14
Lecomte, J	11
Marco, VG	1
Meert, AP	6
Leclercq, N	4
Sculier, JP	19
Okuno, S	1
Petersen, I	1
Shives, T	1
Mahoney, M	1
Haddock, M	1
Sim, F	1
O'Connor, MI	1
Markovic, SN	1
Maples, W	1
Dutour, A	1
Josserand, V	1
Jury, D	1
Guillermet, S	1
Decouvelaere, AV	1
Chotel, F	1
Pointecouteau, T	1
Rizo, P	1
Coll, JL	1
Blay, JY	1
Jaffe, N	2
Zanardi, E	1
Maruzzo, M	1
Montesco, MC	1
Roma, A	1
Rastrelli, M	1
Basso, U	2
Raciborska, A	1
Bilska, K	1
Drabko, K	1
Chaber, R	1
Sobol, G	1
Pogorzała, M	1
Wyrobek, E	1
Połczyńska, K	1
Rogowska, E	1
Rodriguez-Galindo, C	2
Wożniak, W	1
Hung, GY	1
Yen, HJ	1
Yen, CC	1
Chen, WM	1
Chen, PC	1
Wu, HT	1
Chiou, HJ	1
Chang, WH	1
Hsu, HE	1
Kameda, T	1
Takahashi, K	1
Kim, R	1
Jiang, Y	1
Movahed, M	1
Park, EK	1
Rantanen, J	1
Marlier, ME	1
DeFries, RS	1
Voulgarakis, A	1
Kinney, PL	1
Randerson, JT	1
Shindell, DT	1
Chen, Y	2
Faluvegi, G	1
Diss, E	1
Nalabothula, N	1
Nguyen, D	1
Chang, E	1
Kwok, Y	1
Carrier, F	1
Radhakrishnan, K	1
Lee, A	1
Harrison, LA	1
Morris, E	1
Shen, V	1
Gates, L	1
Wells, RJ	2
Wolff, JE	1
Garvin, JH	1
Cairo, MS	1
Eberlein, B	1
Hann, R	1
Eyerich, S	1
Pennino, D	1
Ring, J	1
Schmidt-Weber, CB	1
Buters, J	1
Dickey, AM	1
Trease, AJ	1
Jara-Cavieres, A	1
Kumar, V	1
Christenson, MK	1
Potluri, LP	1
Morgan, JK	1
Shatters, RG	1
Mckenzie, CL	1
Davis, PH	1
Osborne, LS	1
Francetic, T	1
Le May, M	1
Hamed, M	1
Mach, H	1
Meyers, D	1
Cole, PA	1
Chen, J	1
Li, Q	1
Zborowski, M	1
Moore, LR	1
Williams, PS	1
Chalmers, JJ	1
Cooper, BS	1
Hammad, LA	1
Montooth, KL	1
Bögli, S	1
Brown, BM	1
Marletta, M	1
Tretter, C	1
Wagenhofer, M	1
Leontyev, IV	1
Stuchebrukhov, AA	1
Ates, M	1
Demir, V	1
Adiguzel, R	1
Arslan, Z	1
Zan, GH	1
Tan, C	1
Deserno, M	1
Lanni, F	1
Lösche, M	1
Decato, S	1
Bemis, T	1
Madsen, E	1
Mecozzi, S	1
Trabbic, KR	1
De Silva, RA	1
Andreana, PR	1
Wahbeh, H	1
Oken, B	1
Uitto, J	1
Jiang, Q	1
Váradi, A	1
Bercovitch, LG	1
Terry, SF	1
Liu, J	1
Zhao, J	3
Lee, JF	1
Gartung, A	1
Jawadi, H	1
Zhang, W	1
Lominadze, D	1
Lee, MJ	1
Denic, A	1
Wootla, B	1
Zoecklein, L	1
Rodriguez, M	1
Kim, S	1
Nho, K	1
Risacher, SL	1
Inlow, M	1
Swaminathan, S	1
Yoder, KK	1
Shen, L	1
West, JD	1
McDonald, BC	1
Tallman, EF	1
Hutchins, GD	1
Fletcher, JW	1
Farlow, MR	1
Ghetti, B	1
Saykin, AJ	1
Reyt, G	1
Boudouf, S	1
Boucherez, J	1
Gaymard, F	1
Briat, JF	1
Hao, N	1
Gibson, MP	1
Jani, P	1
Wang, X	1
Lu, Y	1
Qin, C	1
Lu, Z	1
Hammond, GB	1
Xu, B	1
Liu, NK	1
Byers, JS	1
Lam, T	1
Lu, QB	1
Sengelaub, DR	1
Xu, XM	1
von Bernstorff, W	1
Irmer, H	1
Menges, P	1
Peters, S	2
Heidecke, CD	1
Busemann, A	1
Li, X	1
Narayanan, S	1
Michaelis, VK	1
Ong, TC	1
Keeler, EG	1
Kim, H	1
McKay, IS	1
Griffin, RG	1
Wang, EN	1
Furlan, L	1
Paczkowska, M	1
Zalewski, P	1
Garbacki, P	1
Talaczyńska, A	1
Krause, A	1
Cielecka-Piontek, J	1
Xu, M	2
Yu, X	2
Ibrahim, ZA	1
Chan, WH	1
Wong, SL	1
Ong, EJ	1
Narihan, MZ	1
Huang, YJ	1
He, AN	1
Sun, YJ	1
Shen, Z	1
Min, DL	1
Yao, Y	2
Pagano, M	1
Baldi, L	1
Gnoni, R	1
Braglia, L	1
Savoldi, L	2
Liu, YP	1
Jin, J	1
Wang, WH	1
Wang, SL	1
Song, YW	1
Fang, H	1
Ren, H	1
Liu, XF	1
Yu, ZH	1
Li, YX	1
Grignani, G	2
Martín-Broto, J	1
Schuler, M	1
Reichardt, P	1
Schönknecht, C	1
Hadjamu, M	1
Oechsner, M	1
Andratschke, N	1
Duma, MN	1
Zhou, Y	1
Xu, Y	1
Zhong, W	1
Wang, M	1
Lee, HS	1
Lee, YG	1
Koo, DH	1
Oh, S	1
Nam, H	1
Song, JU	1
Lim, SY	2
Lee, SS	1
Mituś, JW	1
Blecharz, P	1
Walasek, T	1
Reinfuss, M	1
Jakubowicz, J	1
Kulpa, J	1
Gallo, K	1
Brickman, A	1
Warren, WH	1
Gattuso, P	1
Seder, CW	1
Sun, JD	1
Liu, Q	1
Ahluwalia, D	1
Ferraro, DJ	1
Wang, Y	1
Jung, D	1
Matteucci, MD	1
Hart, CP	1
Wang, B	1
Saha, D	1
Basu, A	1
Maiti, A	1
Rodriguez, E	1
Lee, AC	1
Nodomi, S	1
Umeda, K	1
Okamoto, T	1
Saida, S	1
Hiramatsu, H	1
Adachi, S	1
Heike, T	1
Ranganath, P	1
Kesler, KA	1
Pagliaro, LC	1
Zschäbitz, S	1
Lasitschka, F	1
Hadaschik, B	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
PEI REGIMEN: A THERAPEUTIC OPTION IN SMALL CELL LUNG CANCER? A MONOINSTITUTIONAL EXPERIENCE OF 46 CONSECUTIVE CASES[NCT02324296]		46 participants (Actual)	Observational	1998-12-31	Completed
Functional and Clinical Long-Term Outcome of Ewing Sarcoma Treatment[NCT00824083]		950 participants (Actual)	Observational	2009-07-31	Completed
Chemotherapy-induced Necrosis in Ewing Sarcoma: Which is the Best Scoring Tool[NCT03968471]		474 participants (Actual)	Observational	2019-05-13	Completed
EUROPEAN INTERGROUP COOPERATIVE EWING'S SARCOMA STUDY [EICESS 92][NCT00002516]	Phase 3	0 participants	Interventional	1992-07-31	Active, not recruiting
A Phase II Study Using Autologous Young Tumor-Infiltrating Lymphocytes Derived From Patients With Non-Small Cell Lung Cancer Following Non-Myeloablative Lymphocyte Depleting Preparative Regimen[NCT02133196]	Phase 2	85 participants (Anticipated)	Interventional	2014-10-23	Recruiting
Phase III Trial Comparing 2 Chemotherapy Schedules (Preoperative vs Pre and Postoperative) in Stage I and II NSCLC[NCT00198354]	Phase 3	530 participants (Actual)	Interventional	2001-05-31	Completed
Observational Study on Treatment of Skeletal Ewing Sarcoma at Diagnosis[NCT04845893]		100 participants (Anticipated)	Observational	2021-06-01	Recruiting
A Phase Ⅱ Single-arm Clinical Trial to Investigate the Efficacy and Safety of Vinorelbine-ifosfamide Regimen as Third-line Treatment in Refractory or Recurrent Extensive Small Cell Lung Cancer Patients[NCT01752517]		60 participants (Anticipated)	Observational	2012-12-31	Recruiting
A Phase 1, Open-Label, Dose Escalation Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Combined Oral C-Met/ALK Inhibitor (PF-02341066) and Pan-Her Inhibitor (PF-0299804) in Patients With Advanced Non-Small Cell Lung Cancer[NCT01441128]	Phase 1	20 participants (Actual)	Interventional	2011-09-01	Terminated
Open Label Phase II Study on Glufosfamide Administered as a 60 Minute Infusion Every 3 Weeks in Advanced Non Small Cell Lung Cancer[NCT00005055]	Phase 2	39 participants (Actual)	Interventional	2000-01-31	Completed
RANDOMISED CLINICAL TRIAL OF IFOSFAMIDE, CARBOPLATIN AND ETOPOSIDE WITH MID-CYCLE VINCRISTINE (VICE) VERSUS STANDARD PRACTICE CHEMOTHERAPY IN PATIENTS WITH LIMITED STAGE SMALL CELL LUNG CANCER (SCLC) AND GOOD PERFORMANCE STATUS[NCT00002822]	Phase 3	400 participants (Anticipated)	Interventional	1996-03-31	Completed
A Phase I Trial and Pharmacokinetic Study of the Oral Platinum Analog Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors[NCT01259479]	Phase 1	9 participants (Actual)	Interventional	2010-12-03	Completed
MISTOSUS: Iscador® P (Mistletoe) Immunotherapy To Improve Event Free Survival In Patients With Relapsed Osteosarcoma After Resection Of Pulmonary Metastases[NCT05726383]	Phase 2	32 participants (Anticipated)	Interventional	2023-12-15	Not yet recruiting
Multicenter Observational Study on the Treatment of Patients With Localized Osteosarcoma[NCT04890067]		120 participants (Anticipated)	Observational	2021-07-30	Recruiting
Phase II Multicenter Study Evaluating the Efficacy of Carboplatin-Etoposide Combination in Hormone-resistant Prostate Cancers With Neuroendocrine Differentiation.[NCT00973882]	Phase 2	60 participants (Actual)	Interventional	2005-04-30	Completed
A Phase Ⅱ Randomized Clinical Trial Comparing Vinorelbine-ifosfamide With Gefitinib as Third-line Treatment in Advanced EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients[NCT01749072]	Phase 2	120 participants (Anticipated)	Interventional	2012-12-31	Recruiting
Efficacy and Tolerance Adjuvant High-Dose Thiotepa With Peripheral Stem Cell Rescue Associated With Conventional Chemotherapy in Children and Adults With Relapsed Osteosarcoma[NCT00978471]	Phase 2	44 participants (Actual)	Interventional	2009-07-31	Completed
Impact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)[NCT02734069]		132 participants (Anticipated)	Observational	2016-02-29	Recruiting
(PRO#11307) Phase III Randomized Study of Autologous Stem Cell Transplantation With High-dose Melphalan Versus High-dose Melphalan and Bortezomib in Patients With Multiple Myeloma 65 Year or Older[NCT01453088]	Phase 2	63 participants (Actual)	Interventional	2010-06-24	Terminated (stopped due to Lack of Accrual)
Tandem Autologous Hematopoietic Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma[NCT01241708]	Phase 3	146 participants (Actual)	Interventional	2010-04-08	Completed
A Phase II Trial of Pemetrexed (Alimta [Registered Trademark]) Combined With Sirolimus (Rapamycin, Rapamune [Registered Trademark]) in Subjects With Relapsed or Refractory NSCLC[NCT00923273]	Phase 1/Phase 2	42 participants (Actual)	Interventional	2008-02-29	Terminated (stopped due to Premature closure - investigator left the National Institutes of Health.)
A Study on the Efficacy and Safety of Anlotinib Combined With Docetaxel in the Treatment of Wild-type Advanced Non-squamous Non Small Cell Lung Cancer Patients With Progress After Immunotherapy Plus Chemotherapy as First-line Treatment[NCT04619537]	Phase 2	42 participants (Anticipated)	Interventional	2020-10-08	Recruiting
Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies[NCT00703625]	Phase 1	26 participants (Actual)	Interventional	2008-03-08	Completed
A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodg[NCT00479167]	Phase 2	1 participants (Actual)	Interventional	2007-05-31	Terminated (stopped due to Lack of accrual and interest in study)
A Phase Ⅱ Randomized Controlled Trial to Compare Gefitinib With Docetaxel as Second-line Therapy for Advanced or Metastatic Non-squamous NSCLC Patients With Wild-type EGFR[NCT01755923]	Phase 2	60 participants (Anticipated)	Interventional	2012-12-31	Recruiting
Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable Non-Small-Cell Lung Cancer.[NCT02259621]	Phase 2	45 participants (Anticipated)	Interventional	2014-09-30	Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	Participants (Count of Participants)
Auto Transplant High Dose Melphalan	27
Auto Transplant High Dose Melphalan+Bortezomib	27

Progression free survival of elderly patients with multiple myeloma treated with either high-dose melphalan versus high-dose melphalan and bortezomib at 3 years (NCT01453088)
Timeframe: Participants will be followed post transplant for a minimum of 3 years, and after that may be monitored as part of the study indefinitely

Phase I: Maximum Tolerated Dose (MTD) of Pemetrexed

Intervention	Participants (Count of Participants)
Auto Transplant High Dose Melphalan	13
Auto Transplant High Dose Melphalan+Bortezomib	11

The phase I component of the study are to determine the safety and tolerability of pemetrexed in human subjects with non small cell lung cancer (NSCLC), and to determine the maximum tolerated dose. (NCT00923273)
Timeframe: 5 weeks

Phase I: Maximum Tolerated Dose (MTD) of Sirolimus

Intervention	mg/m^2 (Number)
Treatment Level 1: 3mg Load	500
Treatment Level 2: 6mg Load	500
Treatment Level 3: 6mg Load	500
Treatment Level 4: 10mg Load	500
Treatment Level 5: 15mg Load	500

The phase I component of the study are to determine the safety and tolerability of sirolimus in human subjects with non small cell lung cancer (NSCLC), and to determine the maximum tolerated dose. (NCT00923273)
Timeframe: 5 weeks

Number of Participants With Serious and Non-Serious Adverse Events

Intervention	mg/m^2 (Number)
Treatment Level 1: 3mg Load	10
Treatment Level 2: 6mg Load	10
Treatment Level 3: 6mg Load	10
Treatment Level 4: 10mg Load	10
Treatment Level 5: 15mg Load	10

Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v3.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT00923273)
Timeframe: Date treatment consent signed to date off study, approximately 45 months

Phase II: Clinical Response Rate

Intervention	Participants (Count of Participants)
	Subjects from phase I	8subjects prior peme & 12 subjects peme naive
Treatment Level 1: 3mg Load	4	0
Treatment Level 2: 6mg Load	3	0
Treatment Level 3: 6mg Load	3	0
Treatment Level 4: 10 mg Load	7	20
Treatment Level 5: 15mg Load	5	0

Clinical response is assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) is disappearance of all target lesions. Partial response (PR) at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. Progressive disease (PD) is at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. (NCT00923273)
Timeframe: 21 weeks

ifosfamide and Cancer of Lung